Exploring the neurochemistry of cognitive decline in mild cognitive impairment
Mild cognitive impairment (MCI) represents a preceding phase that can lead to Alzheimer’s Disease (AD) and is defined by accelerated age-inappropriate cognitive decline. Deficits in executive function can be a strong predictor for MCI conversion to AD. Many aspects of executive function are mediated by neurotransmitters. Dysregulation of these are thought to play a significant role in perpetuating inflammation and neurodegeneration.
The aim of Katerina’s study is to decipher the complex link between brain chemical imbalance, inflammation, and cognitive function in MCI. The project uses a multidisciplinary approach, incorporating biochemical and metabolomic analysis, electrophysiology, and cognitive assessment. This project also includes an interventional study that will test the effect of a supplement known to improve cognition on the levels of these biochemicals and metabolic regulators.
Katerina’s project will provide evidence on which biochemical and/or metabolic processes are deviated in MCI. This will provide a greater understanding of the biology behind MCI. This can inform future drug development for treating MCI, by looking at targeting the biological markers identified by this work.
Associate Professor Genevieve Steiner, Dr Edwin Lim